Eisai Co., Ltd. provided funding for fees associated with the submission to the journalДанная публикация подготовлена при финансовой поддержке ООО «Эйсай»Antonelli A., La Motta C. Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells. Med Res Rev 2017;37(6):1299–317. DOI: 10.1002/med.21448Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(2):1229–42. DOI: 10.1089/thy.2006.16.1229Sciuto R., Romano L., Rea S. et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 2009;20(10):1728–35. DOI: 10.1093/annonc/mdp050Gruber J.J., Colevas A.D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):11326. DOI: 10.1634/theoncologist.2014-0313Mazzaferri E.L., Kloos R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63. DOI: 10.1210/jcem.86.4.7407Melmed S., Polonsky K.S., Larsen P.R., Kronenberg H. Howmones and hormone action. Acta Endocrinol (Buchar) 2016;12(1):113.Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol 2006;91(8):2892–9. DOI: 10.1210/jc.2005-2838Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(9):7099–109. DOI: 10.1158/0008-5472.CAN-04-1443Chang Y.S., Adnane J., Trail P.A. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59(5):561–74. DOI: 10.1007/s00280-006-0393-4Brose M.S., Nutting C., Jarzab B. et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 2013;31(18). DOI: 10.1200/jco.2013.31.18_suppl.4Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(7):5459–65. DOI: 10.1158/1078-0432.CCR-07-5270Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71. DOI: 10.1002/ijc.23131Okamoto K., Kodama K., Takase K. et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1):97–103. DOI: 10.1016/j.canlet.2013.07.007Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI: 10.1016/j.ejca.2008.10.026Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI: 10.1056/nejmoa1406470Haddad R.I., Bischoff L., Ball D. NCCN clinical practice guidelines in oncology thyroid carcinoma version 2.2022. J Natl Compr Canc Netw 2022;20(8):925–51. DOI: 10.6004/jnccn.2022.0040Fukuda N., Wang X., Ohmoto A. et al. Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib. Vivo (Brooklyn) 2020;34(2): 709–14. DOI: 10.21873/invivo.11828Brose M.S., Smit J.W.A., Lin C.-C. et al. 1918P final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). Ann Oncol 2020;31(4):S1087. DOI: 10.1016/j.annonc.2020.08.1406Brose M.S., Worden F.P., Newbold K.L. et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III select trial. J Clin Oncol 2017;35(23):2692–9. DOI: 10.1200/JCO.2016.71.6472Tahara M., Schlumberger M., Elisei R. et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer 2017;75:213–21. DOI: 10.1016/j.ejca.2017.01.013Brose M.S., Schlumbeger M., Jeffers M. et al. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase III DECISION trial. Clin Cancer Res 2019;25(24):7470–80. DOI: 10.1158/1078-0432.CCR-18-3439Taylor M.H., Takahashi S., Capdevila J. et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 2021;31(8):1226–34. DOI: 10.1089/thy.2020.0779Sabra M.M., Sherman E., Tuttle R.M. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy. Clin Endocrinol (Oxf) 2019;90(4):617–22. DOI: 10.1111/cen.13941Thomas L., Lai S.Y., Dong W. et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19(3):251–8. DOI: 10.1634/theoncologist.2013-0362Cabanillas M.E., Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 2019;46(1):57–64. DOI: 10.1053/j.seminoncol.2018.11.004